| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 52 | 2023 | 1670 | 3.650 |
Why?
|
| Polymorphism, Single Nucleotide | 67 | 2022 | 2399 | 3.330 |
Why?
|
| Asthma | 43 | 2022 | 977 | 3.050 |
Why?
|
| Genetic Predisposition to Disease | 50 | 2022 | 2338 | 2.430 |
Why?
|
| Genetic Variation | 22 | 2021 | 1371 | 1.720 |
Why?
|
| Chromosome Mapping | 18 | 2018 | 1076 | 1.520 |
Why?
|
| Models, Genetic | 15 | 2019 | 944 | 1.400 |
Why?
|
| Genotype | 36 | 2023 | 1848 | 1.330 |
Why?
|
| Quantitative Trait Loci | 21 | 2021 | 607 | 1.290 |
Why?
|
| Phenotype | 26 | 2021 | 2439 | 1.180 |
Why?
|
| Linkage Disequilibrium | 15 | 2020 | 477 | 1.090 |
Why?
|
| Genetic Association Studies | 8 | 2020 | 294 | 1.010 |
Why?
|
| Alleles | 17 | 2020 | 1135 | 1.010 |
Why?
|
| Software | 9 | 2019 | 665 | 0.980 |
Why?
|
| Genome, Human | 13 | 2018 | 767 | 0.970 |
Why?
|
| Pedigree | 10 | 2019 | 969 | 0.860 |
Why?
|
| Founder Effect | 5 | 2018 | 104 | 0.820 |
Why?
|
| Diabetic Retinopathy | 3 | 2012 | 91 | 0.800 |
Why?
|
| Chromosomes, Human, Pair 6 | 5 | 2012 | 125 | 0.730 |
Why?
|
| Chromosomes, Human, Pair 17 | 6 | 2021 | 111 | 0.720 |
Why?
|
| Models, Statistical | 7 | 2015 | 575 | 0.710 |
Why?
|
| Genetic Linkage | 11 | 2010 | 624 | 0.710 |
Why?
|
| Gene Frequency | 8 | 2017 | 685 | 0.690 |
Why?
|
| Algorithms | 11 | 2019 | 1875 | 0.690 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2012 | 559 | 0.680 |
Why?
|
| Sequence Analysis, DNA | 7 | 2018 | 866 | 0.640 |
Why?
|
| Computational Biology | 5 | 2017 | 542 | 0.630 |
Why?
|
| Genetic Markers | 10 | 2019 | 478 | 0.610 |
Why?
|
| Genetic Loci | 10 | 2019 | 253 | 0.610 |
Why?
|
| Disease | 3 | 2018 | 90 | 0.600 |
Why?
|
| Humans | 119 | 2023 | 89157 | 0.600 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 5 | 2010 | 32 | 0.560 |
Why?
|
| DNA Methylation | 9 | 2023 | 657 | 0.560 |
Why?
|
| Immunoglobulin E | 5 | 2020 | 145 | 0.530 |
Why?
|
| Crohn Disease | 13 | 2010 | 758 | 0.520 |
Why?
|
| HLA Antigens | 4 | 2018 | 227 | 0.510 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 1429 | 0.490 |
Why?
|
| Epigenesis, Genetic | 6 | 2023 | 507 | 0.490 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 481 | 0.460 |
Why?
|
| Rhinitis, Allergic | 3 | 2020 | 45 | 0.440 |
Why?
|
| Gene Expression | 9 | 2021 | 1310 | 0.440 |
Why?
|
| Cytidine Deaminase | 3 | 2009 | 43 | 0.420 |
Why?
|
| Macular Edema | 2 | 2012 | 50 | 0.410 |
Why?
|
| Rhinovirus | 4 | 2023 | 25 | 0.400 |
Why?
|
| Case-Control Studies | 19 | 2019 | 1855 | 0.400 |
Why?
|
| Child | 25 | 2023 | 7154 | 0.400 |
Why?
|
| Transcriptome | 7 | 2019 | 628 | 0.400 |
Why?
|
| Computer Simulation | 9 | 2018 | 1097 | 0.390 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2015 | 387 | 0.390 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 90 | 0.390 |
Why?
|
| Genetics, Population | 3 | 2013 | 405 | 0.380 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2011 | 695 | 0.370 |
Why?
|
| Haplotypes | 9 | 2018 | 637 | 0.360 |
Why?
|
| Epithelial Cells | 5 | 2023 | 688 | 0.350 |
Why?
|
| Gene Expression Regulation | 9 | 2018 | 1975 | 0.350 |
Why?
|
| Male | 50 | 2021 | 42309 | 0.340 |
Why?
|
| Female | 53 | 2021 | 46078 | 0.340 |
Why?
|
| South Dakota | 4 | 2015 | 47 | 0.330 |
Why?
|
| Colitis, Ulcerative | 7 | 2009 | 736 | 0.330 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 30 | 0.330 |
Why?
|
| DNA | 5 | 2013 | 1307 | 0.330 |
Why?
|
| DNA Replication | 1 | 2009 | 170 | 0.320 |
Why?
|
| Respiratory Sounds | 3 | 2021 | 34 | 0.320 |
Why?
|
| Databases, Genetic | 3 | 2011 | 263 | 0.310 |
Why?
|
| Nose | 2 | 2020 | 94 | 0.310 |
Why?
|
| DNA Repair | 2 | 2009 | 362 | 0.300 |
Why?
|
| Protein Isoforms | 1 | 2009 | 274 | 0.300 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2007 | 201 | 0.290 |
Why?
|
| Genetics | 1 | 2006 | 24 | 0.280 |
Why?
|
| Evolution, Molecular | 2 | 2010 | 839 | 0.270 |
Why?
|
| Genetic Techniques | 1 | 2006 | 73 | 0.270 |
Why?
|
| Biometry | 2 | 2015 | 66 | 0.270 |
Why?
|
| Adult | 30 | 2023 | 26542 | 0.260 |
Why?
|
| Risk | 6 | 2018 | 657 | 0.250 |
Why?
|
| Likelihood Functions | 4 | 2009 | 251 | 0.250 |
Why?
|
| Lung | 4 | 2023 | 1258 | 0.240 |
Why?
|
| Child, Preschool | 11 | 2021 | 3721 | 0.240 |
Why?
|
| Cohort Studies | 10 | 2021 | 2864 | 0.230 |
Why?
|
| Genome | 1 | 2006 | 386 | 0.220 |
Why?
|
| Age of Onset | 4 | 2019 | 312 | 0.220 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 540 | 0.220 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 401 | 0.220 |
Why?
|
| Microbiota | 2 | 2020 | 398 | 0.220 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 285 | 0.220 |
Why?
|
| Nasal Polyps | 1 | 2023 | 60 | 0.210 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 2753 | 0.210 |
Why?
|
| Carrier Proteins | 6 | 2017 | 681 | 0.210 |
Why?
|
| Nuclear Family | 2 | 2019 | 92 | 0.210 |
Why?
|
| Risk Factors | 10 | 2021 | 5483 | 0.200 |
Why?
|
| Respiratory Mucosa | 2 | 2020 | 88 | 0.200 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2018 | 124 | 0.200 |
Why?
|
| Adolescent | 16 | 2023 | 9243 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 59 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2017 | 280 | 0.200 |
Why?
|
| Warfarin | 2 | 2013 | 104 | 0.200 |
Why?
|
| Rhinitis | 1 | 2023 | 178 | 0.190 |
Why?
|
| Mexican Americans | 2 | 2017 | 67 | 0.190 |
Why?
|
| Middle Aged | 24 | 2021 | 25910 | 0.190 |
Why?
|
| HLA-G Antigens | 3 | 2013 | 52 | 0.190 |
Why?
|
| Sinusitis | 1 | 2023 | 214 | 0.190 |
Why?
|
| Smoking | 3 | 2023 | 621 | 0.180 |
Why?
|
| Chromatin | 2 | 2020 | 397 | 0.180 |
Why?
|
| Genomics | 3 | 2015 | 761 | 0.180 |
Why?
|
| HLA-DRB1 Chains | 1 | 2020 | 25 | 0.180 |
Why?
|
| Religion | 2 | 2012 | 88 | 0.180 |
Why?
|
| DNA Copy Number Variations | 2 | 2011 | 177 | 0.170 |
Why?
|
| Mutation | 6 | 2012 | 4137 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2017 | 1176 | 0.170 |
Why?
|
| Organ Specificity | 2 | 2018 | 272 | 0.170 |
Why?
|
| Immunity, Mucosal | 2 | 2017 | 69 | 0.170 |
Why?
|
| Young Adult | 12 | 2021 | 6294 | 0.170 |
Why?
|
| Pharmacogenetics | 2 | 2013 | 443 | 0.160 |
Why?
|
| Receptors, Odorant | 2 | 2010 | 37 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2013 | 427 | 0.160 |
Why?
|
| Smad2 Protein | 1 | 2018 | 20 | 0.160 |
Why?
|
| Genomic Imprinting | 1 | 2018 | 33 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 42 | 0.160 |
Why?
|
| CpG Islands | 2 | 2018 | 157 | 0.150 |
Why?
|
| RNA, Untranslated | 1 | 2017 | 65 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 445 | 0.150 |
Why?
|
| Actinobacteria | 1 | 2017 | 11 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1215 | 0.140 |
Why?
|
| Nasopharynx | 1 | 2017 | 50 | 0.140 |
Why?
|
| Infant | 6 | 2021 | 3149 | 0.140 |
Why?
|
| Human Migration | 1 | 2016 | 26 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2011 | 101 | 0.140 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2008 | 77 | 0.140 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2007 | 63 | 0.140 |
Why?
|
| Lipids | 1 | 2017 | 271 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 38 | 0.130 |
Why?
|
| Gene Flow | 1 | 2016 | 91 | 0.130 |
Why?
|
| Parents | 1 | 2019 | 285 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2012 | 529 | 0.130 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2015 | 2 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2013 | 551 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 207 | 0.130 |
Why?
|
| Sputum | 1 | 2015 | 35 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 66 | 0.130 |
Why?
|
| Texas | 3 | 2011 | 113 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2009 | 576 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 106 | 0.120 |
Why?
|
| DNA Mismatch Repair | 3 | 2010 | 55 | 0.120 |
Why?
|
| alpha-N-Acetylgalactosaminidase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Dermatitis, Atopic | 1 | 2015 | 55 | 0.120 |
Why?
|
| Exome | 2 | 2012 | 127 | 0.120 |
Why?
|
| Fatty Acid Desaturases | 1 | 2014 | 17 | 0.120 |
Why?
|
| Bayes Theorem | 3 | 2022 | 369 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 111 | 0.120 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.120 |
Why?
|
| Obesity | 2 | 2018 | 966 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2014 | 684 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 299 | 0.110 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 8 | 0.110 |
Why?
|
| beta-Defensins | 1 | 2013 | 12 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 38 | 0.110 |
Why?
|
| Chemokines, CC | 1 | 2013 | 36 | 0.110 |
Why?
|
| Aged | 13 | 2021 | 19119 | 0.110 |
Why?
|
| Polymorphism, Genetic | 5 | 2011 | 824 | 0.110 |
Why?
|
| Common Cold | 1 | 2013 | 13 | 0.110 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 9 | 0.110 |
Why?
|
| Nod2 Signaling Adaptor Protein | 4 | 2006 | 13 | 0.110 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2012 | 12 | 0.110 |
Why?
|
| Anxiety | 1 | 2015 | 308 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 158 | 0.110 |
Why?
|
| Kallikreins | 1 | 2012 | 49 | 0.100 |
Why?
|
| Genome, Mitochondrial | 1 | 2012 | 27 | 0.100 |
Why?
|
| Base Sequence | 6 | 2016 | 2327 | 0.100 |
Why?
|
| United States | 8 | 2021 | 6965 | 0.100 |
Why?
|
| Privacy | 1 | 2012 | 20 | 0.100 |
Why?
|
| Diabetes Complications | 2 | 2010 | 170 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2015 | 321 | 0.100 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2011 | 5 | 0.100 |
Why?
|
| Craniofacial Dysostosis | 1 | 2011 | 12 | 0.100 |
Why?
|
| Micrognathism | 1 | 2011 | 11 | 0.100 |
Why?
|
| Limb Deformities, Congenital | 1 | 2011 | 20 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2006 | 100 | 0.100 |
Why?
|
| Vestibular Diseases | 1 | 2011 | 27 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 187 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 308 | 0.100 |
Why?
|
| Respiration | 1 | 2013 | 267 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 78 | 0.100 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 1241 | 0.100 |
Why?
|
| Synaptic Membranes | 1 | 2011 | 14 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2012 | 114 | 0.090 |
Why?
|
| Angiopoietins | 1 | 2010 | 6 | 0.090 |
Why?
|
| Multigene Family | 2 | 2010 | 203 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 44 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 48 | 0.090 |
Why?
|
| Mixed Function Oxygenases | 1 | 2011 | 69 | 0.090 |
Why?
|
| Oxidoreductases | 1 | 2011 | 112 | 0.090 |
Why?
|
| Genetic Fitness | 1 | 2010 | 38 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2013 | 196 | 0.090 |
Why?
|
| Animals | 10 | 2013 | 27330 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 359 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2011 | 234 | 0.090 |
Why?
|
| Lod Score | 3 | 2006 | 152 | 0.090 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 53 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 249 | 0.090 |
Why?
|
| Base Pair Mismatch | 2 | 2006 | 27 | 0.090 |
Why?
|
| Olfactory Perception | 1 | 2010 | 21 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 3 | 2018 | 86 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 313 | 0.090 |
Why?
|
| Uracil | 1 | 2009 | 55 | 0.090 |
Why?
|
| Intellectual Disability | 1 | 2011 | 189 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 771 | 0.080 |
Why?
|
| Pre-Eclampsia | 1 | 2012 | 254 | 0.080 |
Why?
|
| Kringles | 1 | 2009 | 6 | 0.080 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2009 | 4 | 0.080 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2009 | 4 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 444 | 0.080 |
Why?
|
| Cortactin | 1 | 2008 | 11 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2009 | 208 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2009 | 144 | 0.080 |
Why?
|
| Self Disclosure | 1 | 2008 | 32 | 0.080 |
Why?
|
| Endocarditis, Bacterial | 1 | 2009 | 38 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 432 | 0.080 |
Why?
|
| Prognosis | 3 | 2016 | 3776 | 0.080 |
Why?
|
| Laser Coagulation | 1 | 2008 | 56 | 0.080 |
Why?
|
| Sample Size | 2 | 2016 | 128 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2009 | 200 | 0.080 |
Why?
|
| Mice | 7 | 2013 | 11743 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 414 | 0.070 |
Why?
|
| Integrin beta3 | 1 | 2007 | 32 | 0.070 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2007 | 41 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 47 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2015 | 66 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2008 | 234 | 0.070 |
Why?
|
| DNA Glycosylases | 1 | 2006 | 25 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2007 | 217 | 0.070 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 36 | 0.070 |
Why?
|
| Programming Languages | 1 | 2006 | 15 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2021 | 2479 | 0.070 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2006 | 37 | 0.070 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2006 | 2 | 0.070 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 9 | 0.070 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2005 | 21 | 0.070 |
Why?
|
| Flagellin | 1 | 2006 | 18 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2005 | 51 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2020 | 2880 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2009 | 836 | 0.060 |
Why?
|
| Research Design | 1 | 2009 | 597 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1547 | 0.060 |
Why?
|
| Child Day Care Centers | 1 | 2005 | 6 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6794 | 0.060 |
Why?
|
| Autophagy | 1 | 2007 | 159 | 0.060 |
Why?
|
| Frameshift Mutation | 2 | 2003 | 51 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2006 | 3376 | 0.060 |
Why?
|
| Insulin | 1 | 2009 | 1146 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 72 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2004 | 86 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 109 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2006 | 537 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2003 | 293 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2006 | 299 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 1867 | 0.060 |
Why?
|
| Homozygote | 2 | 2001 | 204 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2003 | 25 | 0.050 |
Why?
|
| Genes, Duplicate | 1 | 2002 | 19 | 0.050 |
Why?
|
| Peptidoglycan | 1 | 2003 | 31 | 0.050 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2013 | 16 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2023 | 124 | 0.050 |
Why?
|
| Colon | 1 | 2006 | 509 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2013 | 20 | 0.050 |
Why?
|
| Coenzyme A | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2015 | 228 | 0.050 |
Why?
|
| Aging | 1 | 2007 | 716 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2003 | 158 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2021 | 25 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 1063 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2002 | 111 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 245 | 0.050 |
Why?
|
| Family Health | 2 | 2017 | 162 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2000 | 40 | 0.050 |
Why?
|
| Cell Line | 3 | 2018 | 2495 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 805 | 0.050 |
Why?
|
| Heterozygote | 3 | 2011 | 373 | 0.050 |
Why?
|
| Transcription Factors | 3 | 2015 | 1652 | 0.050 |
Why?
|
| Random Allocation | 1 | 2000 | 328 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 948 | 0.040 |
Why?
|
| RNA | 2 | 2015 | 578 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 3003 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1709 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 65 | 0.040 |
Why?
|
| North America | 2 | 2011 | 184 | 0.040 |
Why?
|
| Exons | 2 | 2012 | 451 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1999 | 85 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 85 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2010 | 1990 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 48 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1998 | 54 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1998 | 79 | 0.040 |
Why?
|
| Erythropoietin | 1 | 1998 | 88 | 0.040 |
Why?
|
| Histone Code | 1 | 2017 | 19 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 87 | 0.040 |
Why?
|
| Allergens | 1 | 2018 | 183 | 0.040 |
Why?
|
| Anemia | 1 | 1998 | 129 | 0.040 |
Why?
|
| Biomarkers | 2 | 2017 | 1763 | 0.040 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2017 | 179 | 0.040 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 26 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 232 | 0.040 |
Why?
|
| Leukocytes | 1 | 2017 | 204 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 2347 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 63 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2018 | 471 | 0.030 |
Why?
|
| Cytokines | 3 | 2005 | 802 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 53 | 0.030 |
Why?
|
| Pregnancy | 2 | 2014 | 3011 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 248 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 1157 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 227 | 0.030 |
Why?
|
| Rhode Island | 1 | 2015 | 10 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 786 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2015 | 31 | 0.030 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 36 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 41 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 84 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2015 | 51 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2015 | 48 | 0.030 |
Why?
|
| Genes, MHC Class II | 2 | 2006 | 30 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2014 | 16 | 0.030 |
Why?
|
| Jews | 2 | 2006 | 42 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2016 | 169 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2014 | 49 | 0.030 |
Why?
|
| Costa Rica | 1 | 2014 | 15 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 956 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 163 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2614 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 422 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 12 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 45 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 922 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 519 | 0.030 |
Why?
|
| Transgenes | 2 | 2005 | 185 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2013 | 14 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 868 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2013 | 23 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 139 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2013 | 58 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2012 | 22 | 0.030 |
Why?
|
| Umbilical Cord | 1 | 2012 | 40 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 988 | 0.030 |
Why?
|
| Trophoblasts | 1 | 2012 | 33 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 160 | 0.030 |
Why?
|
| Untranslated Regions | 1 | 2012 | 18 | 0.030 |
Why?
|
| Canada | 1 | 2012 | 208 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 10 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 511 | 0.030 |
Why?
|
| Heredity | 1 | 2011 | 19 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2011 | 50 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2012 | 119 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2011 | 20 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4281 | 0.020 |
Why?
|
| Metabolomics | 1 | 2012 | 75 | 0.020 |
Why?
|
| Immunity, Innate | 2 | 2006 | 429 | 0.020 |
Why?
|
| Mexico | 1 | 2011 | 70 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1488 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3211 | 0.020 |
Why?
|
| Face | 1 | 2011 | 116 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1183 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 230 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 117 | 0.020 |
Why?
|
| Pheromones, Human | 1 | 2010 | 7 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1715 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 87 | 0.020 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 669 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 590 | 0.020 |
Why?
|
| C-Peptide | 1 | 2009 | 179 | 0.020 |
Why?
|
| Siblings | 1 | 2009 | 111 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1837 | 0.020 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2008 | 16 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 1890 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 106 | 0.020 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2008 | 41 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2008 | 293 | 0.020 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2009 | 172 | 0.020 |
Why?
|
| Adipokines | 1 | 2008 | 17 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 661 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 2008 | 33 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 289 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 121 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 449 | 0.020 |
Why?
|
| Lectins | 1 | 2008 | 84 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 895 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 1424 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 283 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 312 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 324 | 0.020 |
Why?
|
| Autophagy-Related Proteins | 1 | 2007 | 21 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2008 | 195 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2007 | 94 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2009 | 318 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 9022 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 348 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2008 | 199 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1940 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2007 | 82 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 645 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2009 | 500 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2006 | 57 | 0.020 |
Why?
|
| Deamination | 1 | 2005 | 6 | 0.020 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2005 | 6 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2006 | 117 | 0.020 |
Why?
|
| RNA Interference | 1 | 2007 | 376 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2007 | 511 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 684 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2005 | 132 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 1296 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 1117 | 0.020 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2004 | 4 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 73 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 98 | 0.010 |
Why?
|
| Microarray Analysis | 1 | 2004 | 96 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 252 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2014 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1720 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2004 | 93 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 543 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 314 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 556 | 0.010 |
Why?
|
| Neoplasms | 1 | 1998 | 3037 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1798 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 8217 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 996 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 887 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 112 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 699 | 0.010 |
Why?
|
| Middle East | 1 | 2000 | 18 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 27 | 0.010 |
Why?
|
| Cytosine | 1 | 2001 | 128 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2002 | 439 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 354 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 740 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1998 | 125 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 1574 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 466 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1998 | 192 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2062 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 200 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3027 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1012 | 0.010 |
Why?
|
| Quality of Life | 1 | 1998 | 1665 | 0.010 |
Why?
|